
MediWound (MDWD) Stock Forecast & Price Target
MediWound (MDWD) Analyst Ratings
Bulls say
MediWound is likely to experience significant growth in the near future due to the potential for their partner Vericel to drive upside to consensus outlook and their EscharEx product offering an attractive alternative to market leader Santyl. Additionally, the company's expanded manufacturing facility in Israel is expected to receive regulatory clearance in the second half of 2026, which will support further revenue growth. Management is also optimistic about the company's revenue guidance for FY26, which remains unaffected by regulatory delays and is supported by a growing list of endorsements for their NexoBrid product.
Bears say
MediWound is facing potential delays in its EscharEx Phase 3 VALUE trial, with added patients likely extending timelines by ~4 months and adding $6M in expenses. The company also reported lower than expected revenues for 1Q26 and maintained a net loss, which could impact future financials and hinder the development of its pipeline products. Additionally, there are various risks, including clinical, regulatory, and financial, that could affect the achievement of the company's price target and success of its products.
This aggregate rating is based on analysts' research of MediWound and is not a guaranteed prediction by Public.com or investment advice.
MediWound (MDWD) Analyst Forecast & Price Prediction
Start investing in MediWound (MDWD)
Order type
Buy in
Order amount
Est. shares
0 shares